DOCSLIB.ORG

Annual Meeting Abstracts May 11–13, 2015

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Meeting Abstracts May 11–13, 2015 MEETING.CIMT.EU | ASSOCIATION FOR CANCER IMMUNOTHERAPY “The right patient for the right therapy.” CANCER IMMUNOTHERAPY 13th CIMT ANNUAL MEETING ABSTRACTS MAY 11–13, 2015 meeting.cimt.eu cimt.eu ABSTRACTS 2015 13TH ANNUAL MEETING MAY 11–13, 2015 Rheingoldhalle Congress Center Mainz, Germany CIMT Abstract List Therapeutic Vaccination Abstract List (001 - 020) No.: Presenter: Short talk: Title: 001 Akers - HLA Class I self-ligandome reveals extreme allelic variability 002 Allen - A novel linear DNA vaccine targeting HPV16 driven malignancies 003 Beckhove yes VXM01, an oral T-cell vaccine targeting VEGFR-2: Further results from a rand- omized, controlled, first-in-man study in pancreatic cancer patients 004 Bialojan - Combined immunotherapy against cancer: Enhanced efficacy of transcutaneous immunization and agonistic CD40 mAb 005 Brown - Local delivery of checkpoint inhibitor antibodies and other therapeutics to tumours by encoding within the oncolytic adenovirus enadenotucirev 006 Buonaguro - Cancer vaccine development for hepatocellular carcinoma – HEPAVAC 007 Cebula - The density of antigen expressing hepatocytes determines the efficacy of thera- peutic vaccination 008 Cerullo - The abstract is withdrawn 009 Chaurasiya - Transcriptionally targeted interleukin-2 gene therapy for breast cancer using mammoglobin promoter 010 Daemen yes A complete reversal of the immunosuppressed tumor environment into an antitu- mor environment upon rationally designed multimodal cancer immunotherapy 011 Deppisch - The combination of trifunctional bispecific antibodies with a CTLA-4-blocking antibody impacts the induction of an immunologic memory in a preclinical mouse model 012 Dilthey - Accurate HLA typing from next-generation sequencing data 013 Frenzel - The GAPVAC consortium: Moving a novel concept of actively personalized can- cer immunotherapy into the clinic 014 Frøsig - Checkpoint inhibitors in cancer immunotherapy: Cross reactivity of a CTLA-4 antibody and IDO-inhibitor L-1MT in pigs 015 Gerer - Immunotherapy of Merkel Cell Carcinoma by therapeutic DC vaccination against the viral oncogenic driver large T antigen 016 Grunwitz - Preclinical evaluation of an mRNA-based immunotherapy against HPV16+ Head and neck squamous cell carcinoma 017 Gustafsson - A novel peptide-conjugate vaccine strategy that targets antigen-presenting cells via endogenous antibodies 018 Harden - Investigation of T-cell responses after DNA vaccination in patients with chronic myeloid leukaemia 019 Heesch - The Mutanome Engineered RNA Immuno-Therapy (MERIT) project: Introducing individualized medicine for the treatment of TNBC 020 Hempel - Vaccinia virus E3-mNRA boosts humoral immune response to self-replicating RNA encoding HA CIMT Abstract List Therapeutic Vaccination Abstract List (021 - 039) No.: Presenter: Short talk: Title: 021 Hinkkanen - Neuron-specific microRNA target repeats engineered in alphavirus RNA genome abrogate lethal phenotype but retain viral ability to replicate in the presence of IFN-I in syngeneic CT-2A glioma model 022 Hirayama - Identification of oncofetal antigen (IMP-3)-derived long peptides encompassing both CTL epitopes and multiple HLA-class II-restricted Th cell epitopes 023 Hobernik - CCL22 regulated plasmid DNA as a promising perspective in DC-specific DNA vaccination 024 Höchst yes Controversial effect of atRA in treatment of non-responders in therapeutical vaccination 025 Høgset - Photochemical internalization - an innovative technology giving strong en- hancement of cytotoxic T-cell responses to vaccination 026 Hoppe - Identification of T cell epitopes for a therapeutic HPV16 vaccine 027 Hoyer - Mimicking of CD4+ T-cell help within DCs by transfection with caIKKRNA to improve DC vaccination 028 Hutzler - Oncolytic measles virus for tumor vaccination 029 Jabulowsky yes Lipo-MERIT: a novel nanoparticular formulated tetravalent RNA cancer vaccine for treatment of patients with advanced melanoma 030 Junco Barranco - Heberprovac, a GnRH based therapeutic vaccine to treat advanced prostate can- cer 031 Kanaseki - Identification of the novel antigenic peptide presented by the cancer stem cells of human colon cancer 032 Kappel - Mannose conjugated HPMA-LMA block copolymer micelles for targeting of anti- gen presenting cells and release of anti-tumor agents 033 Khallouf - Evaluation of different adjuvant systems for an epitope-based therapeutic hu- man papillomavirus vaccine 034 Kloke - IVAC MUTANOME - Evaluation of a new personalized therapeutic modality for the treatment of cancer 035 Kloor - Vaccination of MSI-H colorectal cancer patients with frameshift peptide anti- gens - a phase I/IIa clinical trial 036 Koch - A randomized, double-blind, placebo-controlled, phase I/II Trial of RNActive®- vaccine CV9104 in patients with metastatic castrate-refractory prostate cancer (mCRPC): First results of the phase I part 037 Kowalczyk - Self-adjuvanted RNActive® vaccines provide a promising platform for combina- tion therapies with checkpoint inhibitors 038 Löffler - Constructing a peptide vaccine warehouse for the personalized immunotherapy of colorectal cancer 039 Lövgren - Enhanced IL-12 production and T cell stimulation ability by dendritic cells ma- tured in presence of GMP-grade Toll-like receptor ligands and IFN-γ CIMT Abstract List Therapeutic Vaccination Abstract List (040 - 058) No.: Presenter: Short talk: Title: 040 Mensali - Invariant chain as a vaccination vehicle for colorectal cancer 041 Milenova - Immunotherapy with a CD40L/4-1BBL double-armed oncolytic adenovirus drives Th1 immunity and controls tumor progression in a pancreatic cancer model 042 Occhipinti - Mutated variant of HER2 as a target for immunotherapy in breast cancer 043 Ophir yes Increased anti-tumor immunity that correlates with clinical benefit and induc- tion of neoantigens reactivity following autologous tumor lysate-pulsed den- dritic cells vaccination in recurrent ovarian cancer 044 Overgaard - Elucidating the T-cell reactivity against porcine IDO and RhoC to establish the pig as an animal model for vaccine development against human cancer 045 Ozimkowski - Phenotypic and functional characterization of monocyte derived dendritic cells (MoDC) generated with CliniMACS Prodigy Instrument 046 Palata - Characterization of antigenic profiles of primary non-small cell lung cancer tumors and lung cancer cell lines for vaccine development 047 Pizzurro - Cytokine-matured DC/Apo-Nec melanoma vaccine presents an improved MMP- 9-dependant migration to lymph nodes that can be modulated by the topical use of Imiquimod 048 Podrazil - Immunological parameters in phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer 049 Préville - Modified Vaccinia Virus Ankara therapeutic efficiency in preclinical models of cancer benefits from the blockade of immune checkpoints 050 Rausch - Combined Immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization 051 Reuschenbach - p16INK4a as a vaccine target in patients with HPV-associated cancers - results of a phase I/IIa study 052 Rolih - BoHV-4 viral vector as a new approach for ErbB2+ breast cancer immunotherapy 053 Rothe - Enhancing dendritic cell-induced T-cell responses by immunomodulating mol- ecules 054 Rubinsteyn - Spatial and temporal heterogeneity of mutated tumor antigens in a high grade ovarian serous carcinoma 055 Ruiu - TMPRSS4 is a breast cancer stem cell-associated antigen and a putative target for DNA-based vaccination 056 Sayem - Identification of oncofetal antigen Glypican-3-derived long peptides encompass- ing CTL and multiple HLA class II-restricted Th cell epitopes 057 Schnorfeil - Dendritic cell vaccination in postremission therapy of AML: Results of a clinical phase I trial 058 Sedlik - Effective anti-tumor therapy based on a novel anti-Tn antibody conjugated to a cytotoxic drug CIMT Abstract List Therapeutic Vaccination Abstract List (059 - 075) No.: Presenter: Short talk: Title: 059 Shraibman - Combining chemotherapy with immunotherapy for the treatment of glioblas- toma 060 Stergiou - Fully synthetic Mucin 1 glycopeptides are effective cancer vaccines and induce high antigen-specific antibody titers 061 Tagliamonte - Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma 062 Terhorst - Laser-assisted intradermal delivery of vaccines specific for cross-presenting XCR1+ dendritic cells induces anti-tumoral responses 063 Teulings - Anti-melanoma immunity and local clinical responses of stage III-IV melanoma patients treated with monobenzone and imiquimod; a phase 2a trial 064 Toellner - Vaccines to induce Robo4 and Clec14a specific antibody retard tumour growth 065 Torigoe - Phase I/IIa clinical study of Survivin-2B peptide vaccination in combination with type I interferon for advanced gastrointestinal cancer patients 066 Trautwein - Personalized cancer immunotherapy: patient specific multipeptide vaccination for primary liver cancers 067 Treinies - An RLR/TLR agonist-based combination therapy enhances CTL responses in tumors 068 Tsukahara - Engineering high affinity antibody recognizing naturally presented osteosar- coma antigen PBF peptide 069 Tüttenberg - Sonographic evaluation of lymph node morphology after intranodal vaccination with an RNA-based vaccine in patients with malignant melanoma 070 Uskent - Anti-idiotypic vaccine Racotumomab against NGcGM3 gangloside stabilize disease in rapidly progressing treatment
Load more

Recommended publications
  • Characterization of Increasing Stages of Invasiveness Identifies Stromal/Cancer Cell Crosstalk in Rat Models of Mesothelioma
    www.oncotarget.com Oncotarget, 2018, Vol. 9, (No. 23), pp: 16311-16329 Research Paper Characterization of increasing stages of invasiveness identifies stromal/cancer cell crosstalk in rat models of mesothelioma Joëlle S. Nader1, Jérôme Abadie1,2, Sophie Deshayes1, Alice Boissard3,4, Stéphanie Blandin5, Christophe Blanquart1, Nicolas Boisgerault1, Olivier Coqueret3,4, Catherine Guette3,4, Marc Grégoire1 and Daniel L. Pouliquen1 1CRCINA, INSERM, Université d’Angers, Université de Nantes, Nantes, France 2ONIRIS, Nantes, France 3CRCINA, INSERM, Université de Nantes, Université d’Angers, Angers, France 4ICO, Angers, France 5Plate-Forme MicroPICell, SFR François Bonamy, Université de Nantes, France Correspondence to: Daniel L. Pouliquen, email: [email protected] Keywords: stroma; invasiveness; sarcomatoid mesothelioma; immune cells; rat model Received: November 08, 2017 Accepted: February 25, 2018 Published: March 27, 2018 Copyright: Nader et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Sarcomatoid mesothelioma (SM) is a devastating cancer associated with one of the poorest outcome. Therefore, representative preclinical models reproducing different tumor microenvironments (TME) observed in patients would open up new prospects for the identification of markers and evaluation of innovative therapies. Histological analyses
    [Show full text]
  • Mediated Enamel Mineralization
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Archivio della ricerca- Università di Roma La Sapienza [Frontiers In Bioscience, Landmark, 22, 1289-1329, March 1, 2017] The crossroads between cancer immunity and autoimmunity: antibodies to self antigens Monica Benvenuto1, Rosanna Mattera1, Laura Masuelli2, Ilaria Tresoldi1, Maria Gabriella Giganti1, Giovanni Vanni Frajese3, Vittorio Manzari1, Andrea Modesti1,4, Roberto Bei1,4 1Department of Clinical Sciences and Translational Medicine, University of Rome, Tor Vergata, Rome, 00133 Italy, 2Department of Experimental Medicine, University of Rome, Sapienza, Rome, 00164 Italy, 3Department of Sports Science, Human and Health, University of Rome ‘Foro Italico’, Rome, 00135 Italy, 4Center for Regenerative Medicine, (CIMER), University of Rome “Tor Vergata”, Rome, 00133 Italy TABLE OF CONTENTS 1. Abstract 2. Introduction 3. Immune response to self antigens in cancer patients partly covers that characteristic of patients with autoimmune diseases 4. Features of self antigens involved in the autoreactive immune response: immunological properties and abnormal expression 5. Biological activities of autoantibodies to self antigens 6. Association of autoantibodies to self antigens with paraneoplastic autoimmune syndromes 7. Role of autoantibodies to self antigens as biomarkers for cancer detection and cancer patients prognosis 8. Paraneoplastic neurological syndromes, effects of therapy targeting immune-checkpoint receptors and Tregs dysregulation in autoimmune disease patients: the crossroad between autoimmunity and immune response in cancer patients 9. Conclusions 10. Acknowledgment 11. References 1. ABSTRACT The production of autoantibodies to self meaning of autoantibodies to self antigens detected in antigens is dependent on the failure of immune cancer and autoimmune disease patients.
    [Show full text]
  • Vaccines and Other Immunological Approaches for Cancer Immunoprevention
    Current Drug Targets, 2011, 12, 1957-1973 1957 Vaccines and Other Immunological Approaches for Cancer Immunoprevention Pier-Luigi Lollini*,1, Giordano Nicoletti2, Lorena Landuzzi2, Federica Cavallo3, Guido Forni3, Carla De Giovanni4 and Patrizia Nanni4 1Department of Hematology and Oncological Sciences, University of Bologna; 2Rizzoli Orthopedic Institute, Bologna; 3Molecular Biotechnology Center, Department of Clinical and Biological Sciences, University of Turin; 4Department of Experimental Pathology, University of Bologna, Italy Abstract: The immune system effectively prevents cancer, whereas severe immunodepression increases its incidence. Cancer immunoprevention is a strategy based on the concept that enhancement of tumor immunity in healthy individuals reduces cancer risk. It can be viewed as a kind of chemoprevention. For cancer immunoprevention, the cancer universe can be neatly divided between tumors caused - directly or indirectly - by infectious agents and all other tumors. Immunoprevention of tumors caused by infectious agents is already implemented at the population level for hepatitis B virus (HBV)-related hepatocellular carcinoma and for tumors caused by human papillomaviruses (HPV), like cervical carcinoma. Now the challenge is to develop immunological strategies to prevent the bulk (>80%) of human tumor burden, unrelated to infections. Both vaccines against tumor antigens and immune modulators can prevent tumor onset in cancer- prone mice. These studies outlined the target antigens and the molecular and cellular mechanisms
    [Show full text]
  • Identification of Biomarkers in Colon Cancer Based on Bioinformatic Analysis
    4895 Original Article Identification of biomarkers in colon cancer based on bioinformatic analysis Ying Zhu1#^, Leitao Sun2#^, Jieru Yu3, Yuying Xiang1^, Minhe Shen2^, Harpreet S. Wasan4^, Shanming Ruan2^, Shengliang Qiu2^ 1The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China; 2Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China; 3College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China; 4Department of Cancer Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK Contributions: (I) Conception and design: Y Zhu, L Sun; (II) Administrative support: M Shen, S Ruan, S Qiu; (III) Provision of study materials or patients: Z Ying, L Sun; (IV) Collection and assembly of data: J Yu, Y Xiang; (V) Data analysis and interpretation: Ying Zhu, Leitao Sun, Harpreet S. Wasan, S Qiu, S Ruan; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work. Correspondence to: Shengliang Qiu. Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, 54 Youdian Road, Shangcheng, Hangzhou 310006, China. Email: [email protected]; Shanming Ruan. Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, 54 Youdian Road, Shangcheng, Hangzhou 310006, China. Email: shanmingruan@ zcmu.edu.cn. Background: Colon cancer is one of the most common cancers in the world. Targeting biomarkers is helpful for the diagnosis and treatment of colon cancer. This study aimed to identify biomarkers in colon cancer, in addition to those that have already been reported, using microarray datasets and bioinformatics analysis.
    [Show full text]
  • Vaccines Against Human HER2 Prevent Mammary Carcinoma in Mice Transgenic for Human HER2
    De Giovanni et al. Breast Cancer Research 2014, 16:R10 http://breast-cancer-research.com/content/16/1/R10 RESEARCH ARTICLE Open Access Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2 Carla De Giovanni1,2, Giordano Nicoletti3, Elena Quaglino4, Lorena Landuzzi3, Arianna Palladini1, Marianna Lucia Ianzano1, Massimiliano Dall’Ora1, Valentina Grosso1, Dario Ranieri1, Roberta Laranga1, Stefania Croci1, Augusto Amici5, Manuel L Penichet6, Manuela Iezzi7, Federica Cavallo4, Patrizia Nanni1,2* and Pier-Luigi Lollini1,2 Abstract Introduction: The availability of mice transgenic for the human HER2 gene (huHER2) and prone to the development of HER2-driven mammary carcinogenesis (referred to as FVB-huHER2 mice) prompted us to study active immunopreventive strategies targeting the human HER2 molecule in a tolerant host. Methods: FVB-huHER2 mice were vaccinated with either IL-12-adjuvanted human HER2-positive cancer cells or DNA vaccine carrying chimeric human-rat HER2 sequences. Onset and number of mammary tumors were recorded to evaluate vaccine potency. Mice sera were collected and passively transferred to xenograft-bearing mice to assess their antitumor efficacy. Results: Both cell and DNA vaccines significantly delayed tumor onset, leading to about 65% tumor-free mice at 70 weeks, whereas mock-vaccinated FVB-huHER2 controls developed mammary tumors at a median age of 45 weeks. In the DNA vaccinated group, 65% of mice were still tumor-free at about 90 weeks of age. The number of mammary tumors per mouse was also significantly reduced in vaccinated mice. Vaccines broke the immunological tolerance to the huHER2 transgene, inducing both humoral and cytokine responses.
    [Show full text]
  • Archivio Istituzionale Open Access Dell'università Di Torino Original Citation
    AperTO - Archivio Istituzionale Open Access dell'Università di Torino Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2+mammary cancer This is the author's manuscript Original Citation: Availability: This version is available http://hdl.handle.net/2318/1542810 since 2017-05-16T11:42:46Z Published version: DOI:10.1080/2162402X.2015.1082705 Terms of use: Open Access Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law. (Article begins on next page) 04 October 2021 This is an author version of the contribution published on: Sarah Jacca, Valeria Rolih, Elena Quaglino, Valentina Franceschi, Giulia Tebaldi, Elisabetta Bolli, Alfonso Rosamilia, Simone Ottonello, Federica Cavallo & Gaetano Donofrio Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2+ mammary cancer. In Oncoimmunology, 2015 The definitive version is available at: DOI: 10.1080/2162402X.2015.1082705 1 Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen 2 efficiently protects mice from autochthonous Her-2+ mammary cancer. 3 4 Sarah JaccaaΔ, Valeria RolihbΔ, Elena QuaglinobΔ, Valentina Franceschia, Giulia Tebaldia, Elisabetta 5 Bollib, Alfonso Rosamiliaa, Simone Ottonelloc, Federica Cavallob* and Gaetano Donofrioa* 6 7 aDepartment of Medical-Veterinary Science, University of Parma, Parma, Italy.
    [Show full text]
  • Induce Immunogenic Cell Death Through On-Target Effects
    www.nature.com/cddis ARTICLE OPEN Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects 1,2,3 1,2,3 1,2 1,2 1,2 4 Adriana Petrazzuolo , Maria Perez-Lanzon , Isabelle✉ Martins , Peng Liu , Oliver Kepp , Véronique Minard-Colin , Maria Chiara Maiuri 1,2 and Guido Kroemer 1,2,5,6,7 © The Author(s) 2021 Immunogenic cell death (ICD) is clinically relevant because cytotoxicants that kill malignant cells via ICD elicit anticancer immune responses that prolong the effects of chemotherapies beyond treatment discontinuation. ICD is characterized by a series of stereotyped changes that increase the immunogenicity of dying cells: exposure of calreticulin on the cell surface, release of ATP and high mobility group box 1 protein, as well as a type I interferon response. Here, we examined the possibility that inhibition of an oncogenic kinase, anaplastic lymphoma kinase (ALK), might trigger ICD in anaplastic large cell lymphoma (ALCL) in which ALK is activated due to a chromosomal translocation. Multiple lines of evidence plead in favor of specific ICD-inducing effects of crizotinib and ceritinib in ALK-dependent ALCL: (i) they induce ICD stigmata at pharmacologically relevant, low concentrations; (ii) can be mimicked in their ICD-inducing effects by ALK knockdown; (iii) lose their effects in the context of resistance-conferring ALK mutants; (iv) ICD-inducing effects are mimicked by inhibition of the signal transduction pathways operating downstream of ALK. When ceritinib-treated murine ALK-expressing ALCL cells were inoculated into the left flank of immunocompetent syngeneic mice, they induced an immune response that slowed down the growth of live ALCL cells implanted in the right flank.
    [Show full text]
  • Early Assessment of Colorectal Cancer by Quantifying Circulating Tumor Cells in Peripheral Blood: ECT2 in Diagnosis of Colorectal Cancer
    Article Early Assessment of Colorectal Cancer by Quantifying Circulating Tumor Cells in Peripheral Blood: ECT2 in Diagnosis of Colorectal Cancer Chih-Jung Chen 1,2,3, Wen-Wei Sung 2,3,4,5,6, Hung-Chang Chen 7, Yi-Jye Chern 8, Hui-Ting Hsu 1, Yueh-Min Lin 1,2, Shu-Hui Lin 1,2,9, Konan Peck 8,*,† and Kun-Tu Yeh 1,3,* 1 Department of Surgical Pathology, Changhua Christian Hospital, Changhua 8864, Taiwan; [email protected] (C.-J.C.); [email protected] (H.-T.H.); [email protected] (Y.-M.L.); [email protected] (S.-H.L.) 2 Department of Medical Technology, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli 88637, Taiwan; [email protected] 3 School of Medicine, Chung Shan Medical University, Taichung 8864, Taiwan 4 Department of Urology, Chung Shan Medical University Hospital, Taichung 8864, Taiwan 5 Institute of Medicine, Chung Shan Medical University, Taichung 8864, Taiwan 6 Department of Medical Education, Chung Shan Medical University Hospital, Taichung 8864, Taiwan 7 Department of Colon and Rectal Surgery, Changhua Christian Hospital, Changhua, Taiwan; [email protected] 8 Institute of Biomedical Sciences, Academia Sinica, Taipei 8862, Taiwan; [email protected] 9 Institute of Medicine, Chung Shan Medical University, Taichuang 8864, Taiwan * Correspondence: [email protected] (K.P.); [email protected] (K.-T.Y.); Tel.: +886-4-7238595 (ext. 4830) (K.-T.Y.) † The author, Konan Peck, was deceased during study. Academic Editor: William Chi-shing Cho Received: 13 January 2017; Accepted: 24 March 2017; Published: 31 March 2017 Abstract: Circulating tumor cells (CTCs) in peripheral blood is an indication of poor prognosis for patients with different cancer types.
    [Show full text]
  • Header Type (Not APS)
    New developments in the treatment of anaplastic lymphoma kinase-driven malignancies Luca Mologni & Carlo Gambacorti-Passerini* Dept. Clinical Medicine and Prevention, University of Milano-Bicocca, Via Cadore 48 – 20900 Monza, Italy *Author for correspondence: E-mail: [email protected] Keywords: ALK, tyrosine kinase, crizotinib, lymphoma, NSCLC, targeted therapy Disclosure Carlo Gambacorti-Passerini is PI in the Pfizer protocol A8081013 at the Investigational Site, Monza, Italy. The anaplastic lymphoma kinase (ALK) has been recognized as a therapeutic target in several neoplasias, including anaplastic large cell lymphoma (ALCL), non-small-cell lung cancer (NSCLC), neuroblastoma and colorectal cancer. Both chromosomal rearrangements, leading to the expression of fusion kinases, and kinase-activating point mutations, have been found to trigger the oncogenic activation of ALK. ALK-positive cancers are highly dependent on ALK catalytic activity. Since the normal, wild-type ALK gene is expressed at low levels in a limited population of nervous tissue cells, the targeting of oncogenic ALK proteins has great therapeutic value. Hence, a large effort is ongoing worldwide to develop small-molecule inhibitors of ALK kinase. One compound has been approved for the treatment of ALK+ NSCLC and a number of second- generation compounds is undergoing clinical evaluation. Here, we review the molecular biology of normal and oncogenic ALK, its involvement in the pathogenesis of cancer and the current status of ALK inhibitors research, including preclinical and clinical development and acquired resistance to ALK inhibition. The results obtained so far in ALK+ tumors emphasize the importance of deep understanding of the genetic alterations that cause transformation, in order to achieve major advances in cancer therapy.
    [Show full text]
  • Presentation: Yusuke Nakamura
    From Cancer Genomics to Cancer Treatment : from hope to reality Yusuke Nakamura Human Genome Center Institute of Medical Science The University of Tokyo International HapMap Consortium October 27, 2005 Construction of public database for genetic variations in human Country Genotyping Center %Genome Chromosome Platform Japan RIKEN 24.3% 5, 11, 14, 15, 16, 17, 19 Third Wave Invader Wellcome Trust Sanger UK 23.7% 1, 6, 10, 13, 20 Illumina BeadArray Institute McGill Univ. / Genome Canada 10.1% 2, 4p Illumina BeadArray QuebecWe Innovation (The Centre SNP Research Center in RIKEN) Sequenom MassExtend, China Chinesecontributed HapMap Consortium the largest9.5% 3, SNP8p, 21 data (24.3%) contributed the largest SNP data (24.3%)Illumina BeadArray Illumina among the16.1% SNP 8q,typing 9, 18q, 22, centers X Illumina BeadArray Broad Institute of Harvard and in this paper Sequenom MassExtend, 9.7% 4q, 7q, 18p, Y, mtDNA MIT Illumina BeadArray USA Baylor College of Medicine 4.6% 12 ParAllele MIP PerkinElmer AcycloPrime- UCSF / Washington Univ. 2.0% 7p FP High-denstity Perlegen Sciences All oligonucleotide array Biobank Japan Sample Collection at February 29, 2008 Hyperlipidemia 42,354 Prostate cancer 5,839 Leukemia 1,597 Diabetes 39,982 Periodontitis 5,652 Esophageal cancer 1,461 Cataract 19,070 Pollinosis 5,572 Cervical caner 1,405 Cerebral infarction 16,012 Glaucoma 5,257 Hepatitis B 1,391 Arrhythmia 15,440 Lung cancer 4,845 Uterine corpus cancer 1,189 Stable angina pectoris 14,855 Unstable angina pectoris 4,161 Nephrotic syndrome 1,038 MyocardialWe
    [Show full text]
  • Oncogenic Kinase NPM/ALK Induces Through STAT3 Expression of Immunosuppressive Protein CD274 (PD-L1, B7-H1)
    Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) Michal Marzeca, Qian Zhanga, Ami Goradiaa, Puthiyaveettil N. Raghunatha, Xiaobin Liua, Michele Paesslera, Hong Yi Wanga, Maria Wysockab, Mangeng Chengc, Bruce A. Ruggeric, and Mariusz A. Wasika,1 Departments of aPathology and Laboratory Medicine and bDermatology, University of Pennsylvania, Philadelphia, PA 19104 and cCephalon, West Chester, PA 19380 Communicated by Peter C. Nowell, University of Pennsylvania School of Medicine, Philadelphia, PA, October 29, 2008 (received for review August 27, 2008) The mechanisms of malignant cell transformation caused by the involved in immune evasion in malignancy, as cells of various oncogenic, chimeric nucleophosmin (NPM)/anaplastic lymphoma tumor types have been shown to aberrantly express CD274 and, kinase (ALK) remain only partially understood, with most of the seemingly to a lesser degree, CD273. previous studies focusing mainly on the impact of NPM/ALK on cell Here we report that ALKϩTCL cells universally express survival and proliferation. Here we report that the NPM/ALK- CD274. The CD274 expression is induced in these malignant carrying T cell lymphoma (ALK؉TCL) cells strongly express the cells by the NPM/ALK tyrosine kinase. NPM/ALK triggers the immunosuppressive cell-surface protein CD274 (PD-L1, B7-H1), as expression by activating STAT3, which in turn acts as a determined on the mRNA and protein level. The CD274 expression transcriptional activator of the CD274 gene. These findings is strictly dependent on the expression and enzymatic activity of identify a unique role of NPM/ALK and STAT3 in inducing NPM/ALK, as demonstrated by inhibition of the NPM/ALK function tumor immune evasion, and demonstrate the direct role of an -in ALK؉TCL cells by the small molecule ALK inhibitor CEP-14083 oncogenic protein in controlling the expression of an immu and by documenting CD274 expression in IL-3-depleted BaF3 cells nosuppressive cell-surface protein.
    [Show full text]
  • Predictive Biomarkers for the Efficacy of Peptide Vaccine Treatment
    Shindo et al. Journal of Experimental & Clinical Cancer Research (2017) 36:36 DOI 10.1186/s13046-017-0509-1 RESEARCH Open Access Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer Yoshitaro Shindo1, Shoichi Hazama1,2, Nobuaki Suzuki1, Haruo Iguchi3, Kazuhiro Uesugi3, Hiroaki Tanaka4, Atsushi Aruga5, Takashi Hatori5, Hidenobu Ishizaki6, Yuzo Umeda7, Toshiyoshi Fujiwara7, Tetsuya Ikemoto8, Mitsuo Shimada8, Kazuhiko Yoshimatsu9, Hiroko Takenouchi1, Hiroto Matsui1, Shinsuke Kanekiyo1, Michihisa Iida1, Yasunobu Koki10, Hideki Arima10, Hiroyuki Furukawa10, Tomio Ueno1, Shigefumi Yoshino1, Tomonobu Fujita11, Yutaka Kawakami11, Yusuke Nakamura12, Masaaki Oka13 and Hiroaki Nagano1* Abstract Background: The purpose of the present study was to explore novel biomarkers that can predict the clinical outcome of patients before treatment or during vaccination. These would be useful for the selection of appropriate patients who would be expected to exhibit better treatment outcomes from vaccination, and for facilitating the development of cancer vaccine treatments. Methods: From a single-arm, non-randomized, human leukocyte antigen (HLA)-A-status-blind phase II trial of a vaccine treatment using three HLA-A*2402-restricted peptides for advanced pancreatic cancer (PC), we obtained peripheral blood samples from 36 patients of an HLA-A*2402-matched group and 27 patients of an HLA-A*2402- unmatched group. Results: Multivariate analysis (HR = 2.546; 95% CI = 1.138 to 5.765; p = 0.0231) and log-rank test (p = 0.0036) showed that a high expression level of programmed death-1 (PD-1) on CD4+ T cells was a negative predictive biomarker of overall survival in the HLA-A*2402-matched group .
    [Show full text]